Medical weight management | New York
Zepbound contains tirzepatide and is used with nutrition and activity changes for adult weight management. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It is not interchangeable with a promise of weight loss, insurance approval, or local stock.
Tirzepatide activates GIP and GLP-1 receptors to affect appetite and glucose. The OSA benefit does not mean every cause of snoring or sleep apnea is treated by weight loss.
Adults with obesity, or overweight and a weight-related condition, may qualify for weight treatment. OSA treatment requires the specified sleep-apnea diagnosis and obesity. Clinical review considers pregnancy, severe gastrointestinal problems, other medicines, and treatment continuity.
Confirm the indication and the exact pen or vial presentation. Start with the prescriber’s initiation schedule, learn device-specific administration, and plan nutrition, symptoms, monitoring, and refills. Review the visit, drug benefit, prior authorization, and any savings eligibility separately. Self-pay does not remove clinical monitoring needs.
Bring your weight and treatment history, medicines and supplements, relevant glucose, kidney, and lipid results, and the exact product you have used before. Mention previous side effects, eye disease, eating difficulties, and pregnancy plans. If insurance denied treatment, bring the denial and plan details.
Review a personal or family history of medullary thyroid cancer, MEN 2, severe stomach-emptying problems, pancreatitis, gallbladder disease, allergies, and pregnancy plans before treatment. Nausea, vomiting, constipation, or diarrhea can occur. Persistent severe abdominal pain or inability to keep fluids down needs emergency department assessment now. Call 911 for breathing difficulty, a severe allergic reaction, loss of consciousness or unsafe travel. Tell the anesthesia team about treatment before a procedure. Do not combine GLP-1 medicines or change the dose yourself. Use non-oral contraception or add a barrier method for four weeks after starting and each dose increase. Continue prescribed CPAP or other OSA treatment until the sleep clinician reviews whether it can change.
Review weight trend, appetite, food and fluid intake, bowel symptoms, and treatment tolerability. Check glucose and adjust other diabetes medicines with the prescriber when relevant. Agree on how to contact the team between visits and what to do if a refill is delayed. Continued treatment depends on benefit, safety, access, and your goals.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
Zepbound contains tirzepatide and is used with nutrition and activity changes for adult weight management. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. It is not interchangeable with a promise of weight loss, insurance approval, or local stock. Tirzepatide activates GIP and GLP-1 receptors to affect appetite and glucose. The OSA benefit does not mean every cause of snoring or sleep apnea is treated by weight loss.
The labeled Zepbound starting dose is 2.5 mg under the skin once weekly for four weeks; 2.5 mg is an initiation dose, not a maintenance dose. The prescriber sets subsequent escalation, usually beginning with 5 mg once weekly, according to the indication and tolerability. Learn the exact device and confirm the written schedule rather than start at a higher dose or transfer instructions from another product.
Zepbound is approved for moderate-to-severe OSA in adults with obesity, alongside a reduced-calorie diet and increased activity. It does not establish eligibility for snoring alone or replace the sleep clinician’s treatment plan.
Do not combine or overlap GLP-1 medicines or brands yourself. Product labels do not recommend this combination. The prescriber should review the exact current treatment and write any switch plan.
No. The reviewed Zepbound label includes single-dose pens, single-dose vials, and a multidose KwikPen presentation. Teach administration, storage, and disposal for the exact product dispensed. Label inclusion does not confirm that every presentation or strength is stocked.
The visit, laboratory tests, and medicine can have different coverage rules. Ask the plan about the exact brand and indication, exclusions, prior authorization, required records, deductible, copay, and dispensing route. Bring a denial for review of its specific reason. Nao Medical or the prescriber cannot guarantee approval. Confirm current participation and costs before booking.
Snoring alone does not establish moderate-to-severe obstructive sleep apnea. Bring a diagnostic sleep study and severity information. The clinician decides whether testing or updated records are needed before considering Zepbound’s OSA indication.
Both are once-weekly tirzepatide injections given under the skin of the abdomen or thigh, or in the back of the upper arm with another person’s help. Rotate sites. Use the Instructions for Use for the exact brand and device dispensed: a single-dose pen, single-dose vial, multidose vial and KwikPen require different handling. Get a demonstration before starting or changing devices. Never share a KwikPen. The Mounjaro label does not recommend KwikPen self-administration by pediatric patients or people with visual impairment. Do not mix Mounjaro with insulin in one syringe or estimate a vial dose from another product’s directions.
Both contain tirzepatide, but their approved uses differ. Mounjaro improves glucose control in people with type 2 diabetes age 10 and older. It also reduces the risk of major cardiovascular events in adults with type 2 diabetes at high risk. These events are cardiovascular death, nonfatal heart attack or nonfatal stroke. Zepbound is approved for adult weight management and moderate-to-severe obstructive sleep apnea in adults with obesity. The adult Mounjaro cardiovascular approval does not apply to Zepbound or to children. Prescription, dose and insurance requirements depend on the exact product and indication. Do not combine the brands or switch without a prescriber’s plan.
There is no single best dose for every patient. The labeled maintenance doses for weight reduction are 5, 10 or 15 mg weekly. For obstructive sleep apnea they are 10 or 15 mg weekly. The maximum is 15 mg. The prescriber selects the maintenance dose using response and tolerability after gradual escalation, starting at 2.5 mg weekly for four weeks. Higher doses can produce greater average effects in some trials, but that does not guarantee a better overall choice for you. Do not accelerate increases or use a higher dose because of an advertised price.
The clinician should confirm the adult weight or OSA indication, current BMI, related conditions, prior treatment, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and safe use of the prescribed presentation.
The label starts Zepbound at 2.5 mg under the skin once weekly for four weeks, then increases in 2.5 mg steps after at least four weeks as needed. Weight-management maintenance doses are 5 mg, 10 mg, or 15 mg weekly. Labeled OSA maintenance doses are 10 mg or 15 mg weekly.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy in diabetes, hypersensitivity, and safe use of the specific pen or vial. OSA care should also track sleep symptoms and sleep-medicine follow-up.
The clinician should confirm the adult weight or OSA indication, current BMI, related conditions, prior treatment, and current medicines. The review also covers diabetes and eye history, gastrointestinal or gallbladder concerns, kidney context, pregnancy and procedure plans, contraindications, and safe use of the prescribed presentation.
Follow-up should address response, gastrointestinal effects, hydration and kidney concerns, gallbladder or pancreatitis symptoms, blood glucose when relevant, retinopathy in diabetes, hypersensitivity, and safe use of the specific pen or vial. OSA care should also track sleep symptoms and sleep-medicine follow-up.
Before starting Zepbound, review the prescribed pen or vial, eligibility, costs, side effects and follow-up. If treatment includes obstructive sleep apnea, coordinate with the sleep-care team and continue the prescribed sleep-treatment plan.
An evaluation may lead to another medicine, more testing, a referral, or no medication change.
The health plan and dispensing pharmacy make coverage and fulfillment decisions. Prior authorization may be required.
The clinic cards below show places to start an evaluation. They do not prove that a product is stocked, dispensed, taught, or administered at that site.
Bronx
932 E 174th St, Bronx, NY 10460
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
37-15 23rd Ave, Astoria, NY 11105
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Bronx
2063A Bartow Ave, Bronx, NY 10475
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Brooklyn
341 Eastern Pkwy, Brooklyn, NY 11216
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Long Island
232 W Old Country Rd, Hicksville, NY 11801
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
80-10 Northern Blvd, Jackson Heights, NY 11372
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
90-18 Sutphin Blvd, Jamaica, NY 11435
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Queens
30-07 36th Ave, Astoria, NY 11106
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Long Island
135 Mineola Blvd, Mineola, NY 11501
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Manhattan
259 1st Ave, New York, NY 10003
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Brooklyn
308 Graham Ave, Brooklyn, NY 11211
Choose a nearby clinic for an evaluation and care coordination. Before traveling, confirm the appointment type and any testing, medication teaching or treatment you need.
Explore Nao Medical's broader weight-management program and treatment options.
Review the condition-specific pathway without duplicating broad Zepbound content.
Confirm whether symptoms and clinical context support testing.
Compare a semaglutide treatment with a distinct label and indications.
Review a daily oral option with different administration and interactions.
Content was updated August 2, 2026 from the sources cited here. Medical guidance, prescribing information, medication availability, and insurance rules can change. A licensed clinician must confirm current information and determine each patient's eligibility, testing, treatment, administration setting, and follow-up. Call 911 for a medical emergency. Contact Nao Medical with a question or correction.